Cemacabtagene ansegedleucel

一、开场介绍会议时间：2025年第四季度主持人说明：介绍会议目的为讨论AllogeneTherapeutics2025年第四季度及年末的业务更新和财务业绩；会议正在录制，后续将进入问答环节。管理层发言摘要：ChristineCassiano（首席企业事务与品牌战略官）：介绍参会管理层（DavidChang、ZacharyRoberts、GeoffreyParker），提示会议包含前瞻性陈述，风险因素可参考SEC披露文件。DavidChang（总裁、CEO）：强调2026年为“Allogene定义之年”，细胞疗法进入“以证据为定义的阶段”，重点推进ALPHA3试验（cema-cel）和ALLO-329项目，验证异基因平台的可扩展性与可及性；资金runway延长至2028年第一季度，支持核心试验执行。二、财务业绩分析核心财务数据现金及等价物：截至2025年12月31日，现金、现金等价物及投资为2.583亿美元；2026年2月收到托管资金2370万美元，通过ATM工具额外融资2070万美元。研发费用：2025年Q4为2860万美元（含250万美元非现金股票薪酬），全年1.502亿美元（含1290万美元非现金股票薪酬）。一般及行政费用：2025年Q4为1380万美元（含560万美元非现金股票薪酬），全年5680万美元（含2470万美元非现金股票薪酬）。净亏损：2025年Q4为3880万美元（每股0.17美元，含810万美元非现金股票薪酬），全年1.909亿美元（每股0.87美元，含3760万美元非现金股票薪酬及240万美元长期资产减值）。2026年财务指引：运营现金支出预计约1.5亿美元，GAAP运营费用约2.1亿美元（含3500万美元非现金股票薪酬）。关键驱动因素研发投入集中于ALPHA3和RESOLUTION试验，优先资源支持核心临床项目；通过融资及资金管理延长现金runway至2028年第一季度，覆盖ALPHA3试验入组周期。三、业务运营情况核心业务表现ALPHA3试验（cema-cel）：淋巴瘤领域首个随机研究，评估MRD指导的异基因CAR-T巩固治疗预防复发，计划2026年4月公布中期无效性分析（24例患者MRD清除及安全性数据），目前美国和加拿大有60+活跃站点，澳大利亚、韩国站点启动中。ALLO-329（自身免疫性疾病）：双靶点CD19/CD70CAR-T，整合Dagger技术以减少淋巴耗竭；1期RESOLUTION试验为3+3剂量递增研究，纳入系统性红斑狼疮等风湿病患者，2026年6月预计报告概念验证数据。研发投入与成果2025年研发费用1.502亿美元，重点投入cema-cel和ALLO-329的临床试验设计、患者入组及数据收集；ALLO-329采用低起始剂量（2000万CAR-T细胞），探索无/低淋巴耗竭方案，Dagger技术旨在驱动体内扩增。市场拓展ALPHA3试验覆盖社区与学术中心，约50%为社区站点，部分为“CAR-T新手”中心（无自体CAR-T/移植能力），已实现cema-cel在社区环境中的门诊给药。四、未来展望及规划短期目标（2026年）推进ALPHA3试验：4月公布中期无效性分析（MRD清除差异目标25%-30%），验证cema-cel在社区环境的安全性与可行性；推进ALLO-329项目：6月公布概念验证数据（转化数据及早期临床信号），年底提供额外临床更新；完成ALPHA3试验入组，预计2027年底前完成。中长期战略验证异基因CAR-T平台作为“可扩展、可及、生物制剂规模交付”的必要途径，目标改变一线治疗范式；扩展适应症至自身免疫性疾病，探索ALLO-329在低/无淋巴耗竭下的疗效，推动平台在更多治疗环境中的应用。五、问答环节要点ALPHA3试验设计与数据预期问：中期分析关注的安全参数及社区采用标准？答：重点关注严重不良事件（如住院相关），目标为门诊可交付，社区站点已成功入组，将分享支持社区采用的安全性数据。问：MRD清除差异25%-30%的依据及与ZUMA-7数据的关联性？答：参考ZUMA-7中20%MRD清除差异转化为EFS获益，25%-30%差异预期带来显著临床价值，4月数据将验证这一假设。ALLO-329项目定位问：自身免疫性疾病的目标产品概况？答：ALLO-329设计为低/无淋巴耗竭方案（仅环磷酰胺单天输注，去除氟达拉滨），目标实现B细胞耗竭以重置免疫系统，探索无淋巴耗竭的可能性。市场竞争与定位问：CD3双特异性抗体进入一线治疗对cema-cel市场机会的影响？答：双抗复杂方案在社区采用速度有限，预计未来多年MRD阳性率稳定，cema-cel在社区可及性上具优势。试验入组与站点能力问：ALPHA3社区站点中“CAR-T新手”占比？答：约50%为社区站点，部分无自体CAR-T/移植能力，入组顺利，4月数据更新将提供更多细节。六、总结发言管理层强调2026年为“以证据为定义”的关键年，通过ALPHA3和ALLO-329数据验证异基因CAR-T的核心优势（可扩展性、可及性、持久治愈潜力）；资金储备充足（至2028年第一季度），将以“严谨和速度”推进临床里程碑，让数据指导平台扩展至更多适应症；重申使命：通过现货供应模式将细胞疗法带给更广泛患者，改变癌症及自身免疫性疾病治疗格局。查看业绩会议全文

iStock, Nuthawut Somsuk Dozens of biotechs reported earnings this week. BioSpace recaps key highlights from Capricor Therapeutics, Legend Biotech, Inovio and Allogene. Myriad biotechs reported earnings this week, with stories ranging from Legend Biotech’s near-term goal of hitting profitability this year to Capricor Therapeutics’ regulatory comeback. 2025 was a rollercoaster year for biotech as regulatory uncertainty and a policy focus on drug pricing sent the markets into tumult. While a comeback had been predicted at the beginning of the year, in reality, the first half of 2025 was what law firm Ropes & Grey dubbed a bear market in a report this week. But things looked up in the second half as the industry started to rebound. The M&A stalemate finally broke and many large deals—primarily Pfizer’s contested but ultimately successful bid for Metsera —revived interest. That set the stage for a promising fourth quarter, which the industry is now getting more detail on as these smaller, science-forward companies report earnings for the period and the full year. Below, BioSpace recaps the top news from across the industry’s small innovators. Capricor Preps for Post-Prasad FDA One biotech that had a particularly tough year was Capricor Therapeutics, with the FDA rejecting the Duchenne muscular dystrophy cardiomyopathy cell therapy in July 2025. The therapy reportedly got caught up in FDA infighting, as Nicole Verdun, the agency’s then-top regulator of cell and gene therapies, wanted to hold an advisory committee meeting while her boss, Center for Biologics Evaluation and Research (CBER) Director Vinay Prasad, did not. Last week, Prasad’s departure was announced , potentially clearing the way for Capricor and other biotechs. Indeed, days later, the FDA announced a plan to review the Duchenne cardiomyopathy therapy, called deramiocel, again by August 22. With things back on track, Capricor CEO Linda Marbán told analysts on a Thursday fourth quarter earnings call that no decision has been made on an adcomm—but the biotech is preparing no matter what. FDA ‘Unprecedented’ FDA Leaks Sow Confusion for Patients, Sarepta and Capricor Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy families have turned to the news for answers. Meanwhile, the FDA insists it remains committed to notifying companies of any regulatory action before sharing information with the media or public. August 4, 2025 · 7 min read · Heather McKenzie Read more “I think with the departure of Vinay Prasad, it’s a little bit up in the air as to what’s happening within CBER and what their manifest will be,” Marbán said. “Either way, we’ll be prepared.” The CEO is emboldened by data from the Phase 3 HOPE-3 trial, which was added to the resubmission package for deramiocel in December 2025. The study showed that patients given the cell therapy saw significant improvements in upper-limb and cardiac function compared with those on placebo. The data are “so very strong that I really would be delighted, whether I present it in an AdComm or we proceed directly to PDUFA without it,” Marbán said. A Legend-ary Plan To Make Money in 2026 Legend Biotech is heading toward company-wide profitability this year, thanks to the Johnson & Johnson–partnered CAR T cell therapy Carvykti. The New Jersey– and China-based company reported revenue of $555 million for Carvykti in the fourth quarter , a 5.9% increase compared to the third quarter. This still meant a net loss of $30.9 million for the quarter—but with the cell therapy growing, executives are confident in a goal to reach profitability this year. The drug itself reached profitability in 2025; Legend has $949 million in cash on hand, CEO Ying Huang explained on Legend’s Tuesday earnings call. Cell Therapy 6 Companies Hanging On in Cell Therapy As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, these players are sticking around to take the modality as far as it can go. December 1, 2025 · 9 min read · Tristan Manalac Read more Truist Securities predicts that sales of Carvykti will continue to grow in all quarters of 2026, according to a Thursday note. The firm estimates total revenue of $1.46 billion for 2026. Now or Never for Allogene Elsewhere in cell therapy, Allogene is expecting a make-or-break moment in the second quarter of 2026 with the futility analysis for the Phase 2 ALPHA3 study of CD19 CAR T cema-cel. The trial is testing the therapy in first-line consolidation for large B cell lymphoma, meaning it would be given as an initial treatment to prevent remission. The study is expected to detail minimum residual disease (MRD) clearance, which is a key measure of remission in the disease. The company is hoping to see 30% MRD conversion as compared to the control arm to be clinically meaningful. “We remain bullish on the overall success of ALPHA3 and continue to believe cema-cel has the potential to leapfrog other autologous and allogeneic CD19 CAR-T therapies, remain competitive for longer, and expand the total addressable market,” William Blair wrote in a Friday morning note. Results for ALPHA3 are due in April. Otherwise, Allogene reported a net loss of $38.8 million but $258.3 million in cash on hand, which should provide runway into the first quarter of 2028. A Rocky Regulatory Run for Inovio Inovio’s 2026 could be the biggest in company history, with a drug application finally in front of the FDA after almost 30 years of toiling away in the clinic. The biologics license application for INO-3107, under development for adults with recurrent respiratory papillomatosis, is expected to receive a decision by October 30. While this was a major step forward, executives provided more context on the unique circumstances of this asset’s regulatory review during a fourth quarter earnings call on Thursday . Specifically, the application was granted accelerated review, allowing for marketing without a study showing clinical benefit until a confirmatory one can be conducted. However, the FDA issued a preliminary conclusion that the company has not justified eligibility for the program. Business Inovio Taps New CEO, Drops COVID-19 Vaccine Candidate Jacqueline Shea will take over as the new CEO and announced plans to discontinue its Phase III Innovate trial to prioritize its heterologous booster strategy for COVID-19. May 11, 2022 · 3 min read · Alex Keown Read more Inovio CEO Jacqueline Shea said this was the first time the company had heard of any such issues. “We strongly believe that INO-3107 does fulfill the criteria for review under the accelerated approval program, by meeting an unmet medical need and providing a meaningful therapeutic benefit over existing treatment.” The FDA has agreed to meet with the Inovio team and the company has provided more details, the CEO explained. Meanwhile, commercial plans are continuing ahead of the FDA’s October deadline. That has meant some tough decisions to conserve resources, including eliminating some roles unrelated to advancing INO-3107 to the market. The cuts will help extend Inovio’s cash runway into the fourth quarter of this year, Shea said. The DNA medicine company reported cash on hand of $58.5 million. Analysts from Stephens wrote on Friday that Inovio will need to raise capital to launch INO-3107 if it receives approval. .responsive-container { display: flex; flex-wrap: wrap; border: 1px solid #ededed; font-family: Helvetica, Arial, Sans-Serif; padding: 20px 20px 10px 20px; } .column-left { flex: 1; max-width: 45%; padding: 20px 20px 10px 20px; } .column-right { flex: 2; padding: 20px 20px 10px 20px; } @media (max-width: 768px) { .column-left, .column-right { max-width: 100%; flex: 100%; padding: 10px 0; } } Subscribe to BioPharm Executive! Market insights, trending business and policy stories for biopharma leaders hbspt.forms.create({ region: "na1", portalId: "4413123", formId: "7c139b3c-ff0b-44e0-bffe-f449801dca59", onFormSubmitted: function($form, data) { window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'GTMevent', 'event_name': 'newsletter_sign_up' }); } });